Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells
Creative Medical Technology (NASDAQ: CELZ) has received a Notice of Allowance from the USPTO for a patent application focused on treating Type 1 Diabetes using cell-based immunotherapy. The patent, effective until at least 2040, covers the use of the Company's ImmCelzTM product, which utilizes supercharged T regulatory cells with proprietary cell-free solutions.
The technology has been validated using cells from Type 1 Diabetes patients and aims to address the autoimmune condition where the body attacks insulin-producing beta cells. The patent allowance aligns with the Company's ongoing CREATE-1 clinical trial and strengthens their intellectual property portfolio in regenerative medicine.
Creative Medical Technology (NASDAQ: CELZ) ha ricevuto un Avviso di Concessione dalla USPTO per una domanda di brevetto incentrata sul trattamento del Diabete di Tipo 1 mediante immunoterapia cellulare. Il brevetto, valido almeno fino al 2040, copre l'uso del prodotto ImmCelzTM dell'azienda, che impiega cellule T regolatorie potenziate con soluzioni proprietarie senza cellule.
La tecnologia è stata convalidata utilizzando cellule di pazienti con Diabete di Tipo 1 e mira a contrastare la condizione autoimmune in cui il corpo attacca le cellule beta produttrici di insulina. L'approvazione del brevetto è in linea con lo studio clinico CREATE-1 in corso dell'azienda e rafforza il loro portafoglio di proprietà intellettuale nella medicina rigenerativa.
Creative Medical Technology (NASDAQ: CELZ) ha recibido un Aviso de Concesión por parte de la USPTO para una solicitud de patente centrada en el tratamiento de la Diabetes Tipo 1 mediante inmunoterapia celular. La patente, vigente al menos hasta 2040, cubre el uso del producto ImmCelzTM de la compañía, que utiliza células T reguladoras potenciadas con soluciones propietarias sin células.
La tecnología ha sido validada usando células de pacientes con Diabetes Tipo 1 y busca abordar la condición autoinmune donde el cuerpo ataca las células beta productoras de insulina. La concesión de la patente está alineada con el ensayo clínico CREATE-1 en curso de la compañía y fortalece su portafolio de propiedad intelectual en medicina regenerativa.
Creative Medical Technology (NASDAQ: CELZ)는 세포 기반 면역치료를 이용한 제1형 당뇨병 치료에 관한 특허 출원에 대해 USPTO로부터 허가 통지서를 받았습니다. 이 특허는 최소 2040년까지 유효하며, 회사의 ImmCelzTM 제품 사용을 포함하며, 독자적인 세포 없는 용액과 함께 강화된 T 조절 세포를 활용합니다.
이 기술은 제1형 당뇨병 환자의 세포를 사용하여 검증되었으며, 인슐린을 생산하는 베타 세포를 신체가 공격하는 자가면역 질환을 치료하는 것을 목표로 합니다. 이번 특허 허가는 회사의 진행 중인 CREATE-1 임상시험과 일치하며 재생 의학 분야에서 지적 재산권 포트폴리오를 강화합니다.
Creative Medical Technology (NASDAQ: CELZ) a reçu un avis d'acceptation de la part de l'USPTO pour une demande de brevet portant sur le traitement du diabète de type 1 par immunothérapie cellulaire. Le brevet, valable au moins jusqu'en 2040, couvre l'utilisation du produit ImmCelzTM de la société, qui utilise des cellules T régulatrices surchargées avec des solutions propriétaires sans cellules.
La technologie a été validée avec des cellules de patients atteints de diabète de type 1 et vise à traiter cette maladie auto-immune où le corps attaque les cellules bêta productrices d'insuline. Cette acceptation de brevet est en phase avec l'essai clinique CREATE-1 en cours de la société et renforce son portefeuille de propriété intellectuelle en médecine régénérative.
Creative Medical Technology (NASDAQ: CELZ) hat von der USPTO eine Zulassungsmitteilung für eine Patentanmeldung erhalten, die sich auf die Behandlung von Typ-1-Diabetes mittels zellbasierter Immuntherapie konzentriert. Das Patent, gültig mindestens bis 2040, umfasst die Nutzung des ImmCelzTM-Produkts des Unternehmens, das mit proprietären zellfreien Lösungen verstärkte T-Regulatorzellen verwendet.
Die Technologie wurde mit Zellen von Typ-1-Diabetes-Patienten validiert und zielt darauf ab, die Autoimmunerkrankung zu behandeln, bei der der Körper insulinproduzierende Betazellen angreift. Die Patenterteilung steht im Einklang mit der laufenden CREATE-1-Studie des Unternehmens und stärkt dessen geistiges Eigentum im Bereich der regenerativen Medizin.
- Patent protection secured until at least 2040 for Type 1 Diabetes treatment
- Technology already validated using cells from Type 1 Diabetes patients
- Strengthens IP portfolio in regenerative medicine field
- Aligns with ongoing CREATE-1 clinical trial showing focused development strategy
- None.
PHOENIX, July 17, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application titled, “Prevention and/or Treatment of Type 1 Diabetes by Augmentation of Myeloid Suppressor Cell Activity.”
Once granted, the patent will be in effect until at least 2040.
The patent allows a broad cell-based immunotherapy approach to treating Type 1 diabetes using the ImmCelzTM product, which includes the supercharged T regulatory cells using the Company’s proprietary cell-free solutions. This program has been validated using cells from patients with Type 1 Diabetes.
Type 1 Diabetes is an autoimmune disease in which the body's immune system attacks and destroys insulin-producing beta cells in the pancreas. Because beta cells produce insulin, which is essential for moving glucose (sugar) from the blood into cells for energy, the destruction of these cells leads to a deficiency in insulin and the development of diabetes.
"We believe that the use of ImmCelz to prevent and/or treat Type 1 Diabetes is regenerative immunotherapy in its truest form,” said Timothy Warbington, CEO of Creative Medical. “The treatment of Type 1 Diabetes remains a primary focus for our Company, as evidenced by our ongoing CREATE-1 clinical trial. This issuance protects the integrity of our IP portfolio and reflects the potential of our cell-based therapeutic platform to address multiple unmet medical needs.”
About ImmCelzTM
Creative Medical’s ImmCelz platform utilizes a patient’s own extracted immune cells that are then “reprogrammed/supercharged” by culturing them outside the patient’s body with optimized cell-free factors. The immune cells are then re-injected into the patient from whom they were extracted. The Company believes that this process endows the immune cells with regenerative properties (or “supercharges” them) on top of their original innate functions providing them with the ability to treat multiple indications.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a clinical-stage biotechnology company pioneering regenerative medicine solutions for multiple indications, including pain management, neurology, and urology. The company leverages cutting-edge cell therapy technologies to develop transformative treatments aimed at improving patient outcomes.
For more information, visit www.creativemedicaltechnology.com.
Forward Looking Statements
This news release may contain forward-looking statements including, but not limited to, comments regarding the potential for the Company’s cell-based therapies and the strength of its intellectual property portfolio. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.
Contact:
Creative Medical Technology Holdings, Inc.
IR@CreativeMedicalTechnology.com
Investor Relations:
Devin Sullivan, Managing Director
The Equity Group Inc.
dsullivan@equityny.com
Conor Rodriguez
Associate
crodriguez@equityny.com
FAQ
What patent did Creative Medical Technology (CELZ) receive for Type 1 Diabetes treatment?
How long will Creative Medical's (CELZ) new Type 1 Diabetes treatment patent last?
What is the mechanism of Creative Medical's (CELZ) ImmCelzTM treatment for Type 1 Diabetes?
What clinical trials is Creative Medical (CELZ) conducting for Type 1 Diabetes?
Has Creative Medical's (CELZ) Type 1 Diabetes treatment been validated?
